Production of humanised antibodies to TNFα

Details Production of humanised antibodies to TNFα Production of humanised antibodies to TNFα

2007-03-06

2007-03-06

Hue, Sheela (Department: 1643)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S069100, C435S069600, C435S252330, C435S320100

Reexamination Certificate

active

09949559

ABSTRACT:
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα.

REFERENCES:
patent: 5919452 (1999-07-01), Le et al.
patent: 6350860 (2002-02-01), Buyse et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 392 745 (1990-10-01), None
patent: 2 297 145 (1996-07-01), None
patent: 86/01533 (1986-03-01), None
patent: 89/00195 (1989-01-01), None
patent: 89/01476 (1989-02-01), None
patent: 90/07861 (1990-07-01), None
patent: 91/09967 (1991-07-01), None
patent: 92/11383 (1992-07-01), None
patent: 92/22583 (1992-12-01), None
patent: 93/06231 (1993-04-01), None
patent: 98/20734 (1998-05-01), None
patent: 98/25971 (1998-06-01), None
patent: WO 9909055 (1999-02-01), None
Rudikoff et al. Proc Natl Acad Sci USA 1982 vol. 79 pp. 1979-1983.
William E. Paul, Fundamental Immunology, 3rd ed, pp. 292-295, 1993.
Monaco-Malbet et al. Structure, 8:1069-1077, Oct. 2000.
Pluckthun et al. Immunotechnology 3:83-105, 1997.
Adorini et al., “Pathogenisis and immunotherapy of autoimmune diseases,” Trends in Immunology Today, 18, 209-211, 1997.
Arnett et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis Rheum., 31(1), 315-324, 1988.
Beutler et al., “Shock and tissue injury induced by recombinant human cachetin,” Science, 234, 470-474, 1985.
Bodmer et al., “Preclinical review of anti-tumor necrosis factor monoclonal antibodies,” Critical Care Medicine, 21(10), S441-S446, 1993.
Boers et al., “World Health Organization and International League of Associations for Rheumatology Care Endpoints for Symptom Modifying Antirheumatic Drugs in Rheumatoid Arthritis Clinical Trials,” J. Rheumatol—Supplement 41, 21, 86-89, 1994.
Chapman, A.P. et al., “Therapeutic antibody fragments with prolonged in vivo half lives,” Nature Biotechnology 17, 780-783, 1999.
Crameri et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution,” Nature, 391, 288-291, 1998.
Elliott et al., “Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis,” Lancet, 344, 1105-1110, 1994.
Feldmann et al., Anti-Tumor Necrosis Factor-α Therapy of Rheumatoid Arthritis, Advances in Immunology, 64, 283-350, 1997.
Feldman et al., “Anti-TNF α Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases,” Transplantation Proceedings, 30, 4126-4127, 1998.
Felson et al., American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Athritis, Arthritis Rheum., 38, 727-735, 1995.
Fendly et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor,” Hybridoma, 6(4), 359-370, 1987.
Flanagan et al., “Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing γ,ε and α genes,” Nature, 300, 709-713, 1982.
Hieter et al., Genbank Accession No. J00241 “Human Ig germline kappa-L chain, C region (inv3 allele).” Jan. 5, 1995.
Hieter et al., “Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments,” Cell, 22, 197-207, 1980.
Keffer et al., “Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis,” EMBO J., 10(13), 4025-4031, 1991.
Kirschenbaum et al., “Antibodies to TNF-α: Too little, too late?” Critical Care Medicine, 26(10), 1625-1626, 1998.
Low et al., “Mimicking somatic hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,” J. Mol. Biol., 260, 359-368, 1996.
Maini et al., “Clinical response of Rheumatoid Arthritis (RA) to anti-TNF α (cA2) monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody,” Arthritis Rheum., 38(9), (Supplement) : S186, 1995.
Maini et al., “Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial,” Lancet, 354, 1932-1939, 1999.
Marks et al., “By-passing immunization: Building high affinity human antibodies by chain shuffling,” Bio/Technology, 10, 779-783, 1992.
McKown et al., “Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis,” Arthritis Rheum., 42(6), 1204-1208, 1999.
Meager et al., “Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF),” Hybridoma, 6(3), 305-311, 1987.
Moreland et al., “Etanercept therapy in Rheumatoid Arthritis,” Ann Intern Med., 130, 478-486, 1999.
Patten et al., “Applications of DNA shuffling to pharmaceuticals and vaccines,” Curr. Opin. Biotechnol., 8, 724-733, 1997.
Prevoo et al., “Modified disease activity scores that include twenty-eight-joint counts,” Arthritis Rheum., 38, 44-48, 1995.
Rankin et al., “The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in Rheumatoid Arthritis,” British J. Rheumatology, 34, 334-342, 1995.
Riechmann et al., “Reshaping human antibodies for therapy,” Nature,332, 323-324, 1988.
Scott et al., “Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research,” Clin. Exp. Rheumatol., 10, 521-525, 1992.
Shimamoto et al., “Monoclonal antibodies against human recombinant tumor necrosis factor: preventon of endotoxic shock,” Immunology Letters, 17, 311-318, 1988.
Stephens et al., “Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idotypic responses,” Immunology, 85, 668-674, 1995.
Thompson et al., “Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity,” J. Mol. Biol., 256, 77-88, 1996.
Vaughan et al., “Human antibodies by design,” Nature Biotechnology, 16, 535-539, 1998.
Verhoeyen et al. Science, “Reshaping Human Antobodies: Grafting an Antilysozyme Activity,” 239, 1534-1536, 1988.
Wherry et al., “Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies,” Critical Care Medicine, 21(10), S436-S440. 1993.
Williams et al. “Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis,” PNAS-USA, 89, 9784-9788, 1992.
Wu et al., “An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for anti-body complementarity,” J. Exp. Med., 132, 211-250, 1970.
Yang et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range,” J. Mol. Biol., 254, 392-403, 1995.

Affiliated with

Also associated with

Rating

Production of humanised antibodies to TNFα does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Production of humanised antibodies to TNFα, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of humanised antibodies to TNFα will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3753710